Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Recommendation of “Moderate Buy” by Analysts

Candel Therapeutics, Inc. (NASDAQ:CADL) has been assigned a consensus rating of “Moderate Buy” from the nine research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $18.00.

A number of analysts have issued reports on CADL shares. Zacks Research upgraded shares of Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Cantor Fitzgerald assumed coverage on Candel Therapeutics in a research report on Monday, April 20th. They set an “overweight” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Candel Therapeutics in a research report on Monday, April 20th. Canaccord Genuity Group reissued a “buy” rating and set a $25.00 price objective on shares of Candel Therapeutics in a research report on Friday, March 13th. Finally, Wall Street Zen raised Candel Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, June 1st.

Candel Therapeutics Stock Performance

CADL opened at $9.47 on Friday. The firm has a market cap of $693.87 million, a PE ratio of -9.66 and a beta of -0.49. The company has a quick ratio of 28.05, a current ratio of 28.05 and a debt-to-equity ratio of 0.34. The business has a fifty day simple moving average of $7.91 and a 200-day simple moving average of $6.34. Candel Therapeutics has a fifty-two week low of $4.35 and a fifty-two week high of $9.61.

Candel Therapeutics (NASDAQ:CADL) last announced its earnings results on Thursday, May 14th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.16. As a group, equities analysts predict that Candel Therapeutics will post -0.97 EPS for the current fiscal year.

Hedge Funds Weigh In On Candel Therapeutics

A number of hedge funds have recently made changes to their positions in CADL. Moneta Group Investment Advisors LLC raised its holdings in shares of Candel Therapeutics by 4.9% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 42,517 shares of the company’s stock worth $240,000 after buying an additional 2,000 shares in the last quarter. Invesco Ltd. increased its position in shares of Candel Therapeutics by 29.0% during the 4th quarter. Invesco Ltd. now owns 15,039 shares of the company’s stock worth $85,000 after purchasing an additional 3,380 shares in the last quarter. Janney Montgomery Scott LLC increased its position in shares of Candel Therapeutics by 12.6% during the 1st quarter. Janney Montgomery Scott LLC now owns 30,472 shares of the company’s stock worth $149,000 after purchasing an additional 3,400 shares in the last quarter. MetLife Investment Management LLC increased its position in shares of Candel Therapeutics by 25.5% during the 4th quarter. MetLife Investment Management LLC now owns 19,443 shares of the company’s stock worth $110,000 after purchasing an additional 3,955 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its position in shares of Candel Therapeutics by 128.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock worth $40,000 after purchasing an additional 4,439 shares in the last quarter. Institutional investors and hedge funds own 13.93% of the company’s stock.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.